Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients (AIR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00379418|
Recruitment Status : Completed
First Posted : September 21, 2006
Last Update Posted : September 12, 2013
TITLE: Anti-Ischemic effects of Abciximab(Reopro)
PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor).
INTERVENTION: Heparin vs. heparin + abciximab during PCI
PURPOSE: Measure the effects of abciximab on special healing blood stem cells (EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on microvascular blood flow.
- 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28.
- Measurement of blood flow in selected suitable patients
- 10 minute questionnaire before discharge and on visit on day 28.
|Condition or disease||Intervention/treatment|
|Coronary Artery Disease||Drug: Abciximab|
|Study Type :||Observational|
|Actual Enrollment :||220 participants|
|Official Title:||Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients (AIR)|
|Study Start Date :||January 2003|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||December 2009|
- Drug: Abciximab
Other Name: Reopro
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00379418
|United States, Georgia|
|Atlanta VA Medical Center|
|Atlanta, Georgia, United States, 30033|
|Emory University Hospital|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Arshed A Quyyumi, M.D.||EUH|